Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.

Gynecologic oncology - 1 Sept 2024

Wilhite Annelise M, Wu Sharon, Xiu Joanne, Gibney Geoffrey T, Phung Thuy, In Gino K, Herzog Thomas J, Khabele Dineo, Erickson Britt K, Brown Jubilee, Rocconi Rodney P, Pierce Jennifer Y, Scalici Jennifer M, Jones Nathaniel L

Abstract excerpt

OBJECTIVE: Our goal was to compare molecular and immune profiles of vulvovaginal melanoma (VVM) with cutaneous melanoma (CM) and explore the significance of immune checkpoint inhibitor (ICI) agents on survival. METHODS: Samples from VVM and CM tumors underwent comprehensive molecular and immune profiling. Treatment and survival data were extracted from insurance claims data and OS was calculated from time of ICI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to ATRX gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SF3B1 gene

Share to Immune Checkpoint Inhibitors

Share to Melanoma

Share to Mutation

Share to Skin Neoplasms

Share to Vulvar Neoplasms

Source

Identifiers

PMID: 38861917
DOI: 10.1016/j.ygyno.2024.06.002

Genes

ATRX
BRAF
KIT
SF3B1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.PMID 38861917Read ↗

Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.Semantic proximity Read ↗

Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.Semantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapySemantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Genetic alterations defining human primary melanoma and mechanisms of immune evasionSemantic proximity Read ↗

Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival.Semantic proximity Read ↗

Integrated Spatial Multi-omic Profiling Identifies HSV-associated Inflammatory Macrophage Niches Linked to Oncolytic Virotherapy Response in MelanomaSemantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Mucosal Melanoma: Epidemiology, Biology and Treatment.Semantic proximity Read ↗

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive ReviewSemantic proximity Read ↗

Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.